Portfolia Launches Women's Health Fund IV, Building on its 46-Company Women's Health Portfolio
News provided by Portfolia //Aug 27, 2025, 09:00 ET
First investment in biotech innovator Gameto underscores multi-billion-dollar market potential
SAN FRANCISCO, Aug. 27, 2025 /PRNewswire/ -- Today, Portfolia , the premier investing fund designed for the world's most powerful community of women investors, announced the launch of Women's Health Fund IV, its most focused and forward -looking strategy yet in women's health innovation.
Fund IV's debut investment is in Gameto, a clinical-stage biotechnology company reprogramming female cells to transform fertility and hormonal care. Portfolia's investment is part of Gameto's recently announced $44 million Series C financing, bringing its total raised capital to $127 million, one of the largest investments in the U.S. biopharma sector focused on reproductive health to date. Gameto's lead program, Fertilo, uses engineered ovarian support cells to mature eggs outside the body, reducing the standard two-week IVF hormone protocol to just 2–3 days. The company has begun enrolling patients in its pivotal Phase 3 trial in the U.S., building on its clinical use in Australia and Latin America, with five babies born and over 20 pregnancies recorded so far.
Women's Health Fund IV builds on Portfolia's position as the first venture capital fund focused on women's health in the US, and one of the most active women's health investors in the U.S., with 46 health investments across fertility, childbirth, menopause, autoimmune disease, oncology, cardiovascular health, mental health, nutrition, longevity, and more. Previous funds have backed breakout companies such as Maven Clinic , the first U.S. unicorn in women's health, as well as HeraBiotech , Inherent Biosciences , Mirvie , OsteoBoost , FEMDx , and unicorn, EverlyHealth .
The women's health market is currently estimated at $600B+ globally, spanning high-growth sub-sectors like menopause ($20B), fertility ($50B+), and female-focused longevity therapeutics ($20B). These categories are often undervalued or overlooked by traditional venture capital.
Today, women's health receives just 2% of health-related venture capital funding. McKinsey & Company has projected that closing the gender health gap could yield up to $1 trillion in annual economic benefits by 2040, with significant market opportunities in specific conditions. For example, endometriosis alone represents an estimated $180–$250 billion market, on par with diabetes, according to the NIH and McKinsey.
"At Portfolia, we activate women to invest in the health solutions that will enhance our lives," said Trish Costello, Founder & CEO of Portfolia. "Women's health is compromised daily when investment dollars are not available to fuel new women's health innovations. Women now control nearly $25 trillion of wealth in the U.S., yet we are rarely at the table as early investors, making those decisions that will bring us returns and impact. Our investments bring new solutions to the marketplace from fertility to autoimmune disease to menopause and beyond. Women's Health Fund IV gives all investors access and influence to create this change."
Despite making 80% of healthcare decisions, women face persistent gaps in diagnosis, treatment, and quality of care. Women's Health Fund IV targets three major categories: women-specific conditions such as fertility, menopause, maternal health, gynecology, and women's oncology; conditions that affect women differently, including cardiovascular disease, diabetes, and Alzheimer's disease; and conditions that disproportionately affect women, such as autoimmune disease, osteoporosis, anxiety and depression, lung cancer, and eating disorders.
By aggregating the capital, networks, and expertise of its members, Portfolia invests in early- to growth-stage companies with strong potential for both impact and returns. Women's Health
Fund IV Partners Nola Masterson ; Faz K. Bashi, MD ; Sonia Arrison ; Jennifer Fried ; Delphine O'Rourke , and Trish Costello are seasoned leaders in biotech, venture capital, longevity, healthcare law, and operations, bringing an average of 15+ years of investing experience and deep sector networks.
Women's Health Fund IV is now open to accredited investors, qualified purchasers, and family offices. To learn more or make your investment, visit https://www.portfolia.co/womens-health-iv .
About Portfolia
Portfolia is the world's most powerful investing community, designed for women but open to all. With nearly 2,000 investing members in 20 countries and 50 states, Portfolia's 15 funds have made over 165+ investments in Pre-Seed to Pre-IPO companies. Portfolia venture funds aggregate assets for change. Learn more about Portfolia's investment model or our open funds, by visiting our website at http://portfolia.com/ or email investorrelations@portfolia.com.
